Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry

Movement Disorders

Volumn 25, Issue 15, 2010, Pages 2604-2612

  Köllensperger, Martin ^a   Geser, Felix ^a   Ndayisaba, Jean Pierre ^a   Boesch, Sylvia ^a   Seppi, Klaus ^a   Ostergaard, Karen ^b   Dupont, Erik ^b   Cardozo, A ^c   Tolosa, Eduardo ^c   Abele, Michael ^d   Klockgether, Thomas ^d   Yekhlef, Farid ^e   Tison, Francois ^e   Daniels, Christine ^f   Deuschl, Günther ^f   Coelho, Miguel ^g   Sampaio, Cristina ^g   Bozi, Maria ^h   Quinn, Niall ^h   Schrag, Anette ⁱ   Mathias, Chris J ^j   Fowler, Clare ^k   Nilsson, Christer F ^l   Widner, Håkan ^l   Schimke, Nicole ^m   Oertel, Wolfgang ^m   Del Sorbo, Francesca ⁿ   Albanese, Alberto ⁿ   Pellecchia, Maria Teresa ^o   Barone, Paolo ^o   Djaldetti, Ruth ^p   Colosimo, Carlo ^q   Meco, Giuseppe ^q   Gonzalez Mandly, Antonio ^r   Berciano, Jose ^r   Gurevich, Tanya ^s   Giladi, Nir ^s   Galitzky, Monique ^t   Rascol, Olivier ^t   Kamm, Christoph ^u   Gasser, Thomas ^u   Siebert, Uwe ^v,w   Poewe, Werner ^a   Wenning, Gregor K ^a   more..

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF BONN   (Germany)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF KIEL   (Germany)

^g HOSPITAL DE SANTA MARIA   (Portugal)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^j ST MARY S HOSPITAL   (United Kingdom)

^k NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^l LUND UNIVERSITY   (Sweden)

^m PHILIPPS UNIVERSITY MARBURG   (Germany)

ⁿ DEPARTMENT OF NEUROSURGERY   (Italy)

^o UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^p RABIN MEDICAL CENTER   (Israel)

^q SAPIENZA UNIVERSITY OF ROME   (Italy)

^r HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^s TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^t UNIVERSITÉ PAUL SABATIER   (France)

^u UNIVERSITY OF TÜBINGEN   (Germany)

^v Department for Public Health   (Australia)

^w HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

EMSA SG; Multiple system atrophy; Natural history

Indexed keywords

AMANTADINE; CATECHOL METHYLTRANSFERASE INHIBITOR; DIHYDROERGOTAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUDROCORTISONE; LEVODOPA; MIDODRINE; MONOAMINE OXIDASE B INHIBITOR; OXYBUTYNIN; TOLTERODINE;

ARTICLE; CEREBELLAR ATAXIA; CLINICAL FEATURE; DISEASE DURATION; DYSAUTONOMIA; DYSKINESIA; DYSTONIA; EUROPE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROGENIC BLADDER; ONSET AGE; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRIORITY JOURNAL; REGISTER; SHY DRAGER SYNDROME; SLEEP DISORDER; URINARY DYSFUNCTION;

AGE OF ONSET; ANTIPARKINSON AGENTS; CEREBELLAR ATAXIA; EUROPE; FEMALE; HUMANS; HYPOTENSION, ORTHOSTATIC; LEVODOPA; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSONIAN DISORDERS; REGISTRIES; SHY-DRAGER SYNDROME;

EID: 78349241725     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23192     Document Type: Article

References (35)

1. Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 1998; 8: 359-362.
2. Chrysostome V, Tison F, Yekhlef F, Sourgen C, Baldi I, Dartigues JF. Epidemiology of multiple system atrophy: a prevalence and pilot risk factor study in Aquitaine, France. Neuroepidemiology 2004; 23: 201-208.
3. Schrag A, Ben Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354: 1771-1775.
4. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997; 49: 1284-1288.
5. Hanna PA, Jankovic J, Kirkpatrick JB. Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol 1999; 56: 90-94.
6. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997; 12: 133-147.
7. Wullner U, Schmitz-Hubsch T, Abele M, Antony G, Bauer P, Eggert K. Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German competence network on Parkinson's disease. J Neural Transm 2007; 114: 1161-1165.
8. Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002; 125 (Part 5): 1070-1083.
9. Geser F, Seppi K, Stampfer-Kountchev M, et al. The European multiple system atrophy-study group (EMSA-SG). J Neural Transm 2005; 112: 1677-1686.
10. Geser F, Wenning GK, Seppi K, et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA study group (EMSA SG). Mov Disord 2006; 21: 179-186.
11. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 745-752.
12. Ito T, Sakakibara R, Yasuda K, et al. Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord 2006; 21: 816-823.
13. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 2001; 71: 600-606.
14. The Consensus Committee of the American Autonomic Society and the American Academy of N. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 1996; 46: 1470.
15. Low PA, Opfer-Gehrking TL, McPhee BR, et al. Prospective evaluation of clinical characteristics of orthostatic hypotension. Mayo Clin Proc 1995; 70: 617-622.
16. Mathias CJ, Mallipeddi R, Bleasdale-Barr K. Symptoms associated with orthostatic hypotension in pure autonomic failure and multiple system atrophy. J Neurol 1999; 246: 893-898.
17. Romanzi LJ. Urinary incontinence in women and men. J Gend Specif Med 2001; 4: 14-20.
18. Lemack GE, Dewey RB, Jr, Roehrborn CG, O'Suilleabhain PE, Zimmern PE. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease. Urology 2000; 56: 250-254.
19. Kollensperger M, Stampfer-Kountchev M, Seppi K, et al. Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. Eur J Neurol 2007; 14: 66-72.
20. Zesiewicz TA, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Mov Disord 2000; 15: 305-308.
21. Hughes AJ, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992; 55: 1009-1013.
22. Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125 (Part 4): 861-870.
23. Wenning GK. Placebo-controlled trial of amantadine in multiple-system atrophy. Clin Neuropharmacol 2005; 28: 225-227.
24. Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994; 117 (Part 4): 835-845.
25. Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004; 19: 1391-1402.
26. Ghorayeb I, Yekhlef F, Chrysostome V, Balestre E, Bioulac B, Tison F. Sleep disorders and their determinants in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002; 72: 798-800.
27. Iranzo A. Sleep and breathing in multiple system atrophy. Curr Treat Opt Neurol 2007; 9: 347-353.
28. Vetrugno R, Liguori R, Cortelli P, et al. Sleep-related stridor due to dystonic vocal cord motion and neurogenic tachypnea/tachycardia in multiple system atrophy. Mov Disord 2007; 22: 673-678.
29. Schrag A, personal communication.
30. Schrag A, Selai C, Mathias C, et al. Measuring health-related quality of life in MSA: the MSA-QoL. Mov Disord 2007; 22: 2332-2338.
31. Perala J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007; 64(1): 19-28.
32. Poewe W. Psychosis in Parkinson's disease. Mov Disord 2003; 18 (Suppl 6): S80-S87.
33. Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry 2008; 79: 652-655.
34. Poewe W, Wenning G. The differential diagnosis of Parkinson's disease. EurJ Neurol 2002; 9 (Suppl 3): 23-30.
35. Krim E, Yekhlef F, Chrysostome V, Ghorayeb I, Tison F. [Multiple system atrophy: prognostic factors in the "MSA-Aquitaine" cohort.]. Rev Neurol (Paris) 2007; 163: 54-65.